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The inflammatory response associated with myocardial and brain ischemia/reperfusion
injury (IRI) is a critical determinant of tissue necrosis, functional organ recovery, and
long-term clinical outcomes. In the post-ischemic period, reactive oxygen species
(ROS) are involved in tissue repair through the clearance of dead cells and cellular
debris. Neutrophils play a critical role in redox signaling due to their early recruitment
and the large variety of released ROS. Noteworthy, ROS generated during IRI have
a relevant role in both myocardial healing and activation of neuroprotective pathways.
Anatomical and functional differences contribute to the responses in the myocardial
and brain tissue despite a significant gene overlap. The exaggerated activation of this
signaling system can result in adverse consequences, such as cell apoptosis and
extracellular matrix degradation. In light of that, blocking the ROS cascade might have
a therapeutic implication for cardiomyocyte and neuronal loss after acute ischemic
events. The translation of these findings from preclinical models to clinical trials has
so far failed because of differences between humans and animals, difficulty of agents to
penetrate into specific cellular organs, and specifically unravel oxidant and antioxidant
pathways. Here, we update knowledge on ROS cascade in IRI, focusing on the role
of neutrophils. We discuss evidence of ROS blockade as a therapeutic approach for
myocardial infarction and ischemic stroke.
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INTRODUCTION
Neutrophil (PMN) activation is strongly implicated in the pathogenesis of cardiovascular (CV)
disease (Bonaventura et al., 2019). In addition to favoring atherosclerotic plaque vulnerability and
rupture (Carbone et al., 2015a, 2018b), PMNs enhance thrombosis through different mechanisms,
which include generation of neutrophil extracellular traps (NETs) (Bonaventura et al., 2018),
release of proteases, and direct PMN–platelet interactions (Lisman, 2018). PMNs also have a
critical role in ischemia/reperfusion injury (IRI) (Carbone et al., 2013; Garcia-Culebras et al.,
2018) and tissue repair (Montecucco et al., 2017) (e.g., in the myocardium and the brain).
Oxidative burst characterizes PMN activation and generates several classes of reactive oxygen
species (ROS). Among the different subtypes of NADPH oxidases (NOX), NOX2 is prevalent but
not specific of PMNs, being commonly expressed in cardiomyocytes, endothelial cells, fibroblasts,
and neurons (El-Benna et al., 2009). Components of NOX2 enzymatic complex are located either
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in the cytosol (p47phox/p67phox/p40phox and the GTPase
Rac1/Rac2) or in the plasma membrane (flavocytochrome
subunits gp91phox and p22phox). Once assembled, the
glycosylated gp91phox subunit undergoes a conformational
change which allows catalytic activity. Activated NOX2 then
generates high concentration of superoxide anion (O·−2 ), which
exerts a prevalent local effect due to the short life span. In
addition, O·−2 dismutation may generate hydrogen peroxide
(H2O2), which, in turn, reacts to produce the hydroxyl radical
(·OH). The phagocyte-specific enzyme myeloperoxidase (MPO)
catalyzes the formation of hypochlorous acid (HClO) and
promotes the generation of chloramines, aldehydes, 1O2, ozone
(O3), and ·OH (Prokopowicz et al., 2012). Nitric oxide synthase
(NOS) is another ROS-generating enzyme active in PMNs.
Through the conversion of the L-arginine to L-citrulline, NOS
produces nitric oxide (NO), which may generate peroxynitrite
by interacting with O·−2 (Szabo et al., 2007). On this basis, it is
not surprising that oxidative stress largely contributes to IRI.
Conversely, less is known about the potential involvement in
tissue repair. In the next paragraphs, we will focus on both
myocardial and brain remodeling, also discussing the potential
therapeutic implication of oxidative stress modulation.
NEUTROPHIL OXIDATIVE BURST:
TARGETS AND SIGNALING
Neutrophil-derived ROS show a specific diffusion range,
determined by their life span and reactivity, whereas O·−2
has a short life span. The non-radical compound H2O2
generated by its dismutation readily diffuses across membranes.
Therefore, ROS may differently oxidize DNA, RNA, protein,
and lipids. Nucleic acids undergo direct oxidative processes
(e.g., nitrosative deamination, oxidation, and halogenation) or
alternatively generate adducts with oxidized polyunsaturated
fatty acids, protein, carbohydrates, and even nucleic acids
themselves (Lonkar and Dedon, 2011). Posttranslational
modification of proteins may occur through a direct oxidation
of amino acids or other cellular components. Endoplasmic
reticulum is extremely sensitive to the redox stress, which may
determine disruption of the protein folding mechanism and the
production of misfolded proteins (Cao and Kaufman, 2014).
Also, catabolic processes are under the control of oxidative
stress, which modulates protein degradation and autophagy
(Pajares et al., 2015). By targeting polyunsaturated fatty
acids, ROS may also determine membrane permeability,
cytosol eﬄux, loss of membrane protein activities, and
even biomembrane disruption with loss of cell viability
(Jaganjac et al., 2016).
Finally, ROS may themselves act as second messengers
and then transduce signals. Mitogen-activated protein kinases
(MAPKs) are regulated by oxidative stress via different signaling
cascades, involving Jun, p38 or extracellular signal-regulated
kinase (ERK) 1/2 pathways, protein kinase C (PKC) and
phosphoinositide 3-kinase (PI3K) activation (Hotamisligil and
Davis, 2016). By adding an additional level of control,
oxidative stress regulates a large amount of transcription factors
(e.g., hypoxia-inducible factor [HIF]-1, activator protein [AP]-
1, nuclear factor κ-light-chain-enhancer of activated B cells
[NF-kB], and p53). It is then not surprising that ROS strongly
influence in both autocrine and paracrine manner different
PMN functions including phagocytosis, cytokine secretion, and
apoptosis. Noteworthy, PMN-derived ROS also drive tissue
response to IRI by modulating pathophysiological processes of
resident cells (e.g., cardiomyocytes, endothelial and microglial
cells, and neurons). The following paragraph will focus on
this complex interaction between PMNs and the surrounding
environment (Figure 1).
NEUTROPHIL OXIDANTS AND
MYOCARDIAL REMODELING
Myocardial reperfusion after an acute myocardial infarction
(AMI) is recommended to save as much myocardium as
possible from necrosis and dysfunction. Anyway, when the
coronary flux is re-established, and the myocardium reperfused
after ischemia, the hypercontracture of cardiac myocytes and
their cytolysis may be paradoxically increased in response to
reoxygenation. This phenomenon, known as “oxygen paradox,”
forms a complementary dyad with the oxidative stress (Davies,
2016). The term “myocardial reperfusion injury” (MRI) describes
myocardial injury and cardiomyocyte death usually occurring
between 6 and 24 h after reperfusion of an ischemic area
(Hausenloy and Yellon, 2016). Importantly, MRI is the main
cause of death for stunned cardiomyocytes and ultimately
accounts for more than half of the final size of myocardial
ischemia. As widely reported in clinical and experimental studies,
cardiomyocyte exposure to ROS causes apoptosis through
different mechanisms. The leading one is likely the cytosolic
and mitochondrial calcium overload that determines rapid
alteration of intracellular pH. This, in turn, triggers the activation
of MAPKs (Ong et al., 2015). Of interest, recent studies
hypothesized oxidative stress as a promoter of myocardial fibrosis
after ischemic injury, and both angiotensin 1 and the KCa3.1
channel have been suggested as involved pathways (Somanna
et al., 2016; Wang et al., 2017). PMNs are recruited very early
to the infarcted area (nearly after 30 min), and their actions
are mediated by adhesive interactions with vascular endothelial
cells, such as selectins, integrins, and molecules belonging to
the immunoglobulin superfamily (Bonaventura et al., 2016).
Selectin-dependent adhesion of PMNs mainly involves L-selectin
(CD62L), E-selectin (CD62E), and P-selectin (CD62P). They play
a critical role in neutrophil rolling so that their blocking is
effective in reducing PMN recruitment and infarct size (Weyrich
et al., 1993; Palazzo et al., 1998). However, selectins alone do
not allow transmigration until the integrins start to play. PMNs
express a combination of the β-chain CD18 with the α-chains
CD11a [LFA-1 (lymphocyte function-associated antigen-1)],
CD11b (macrophage-1 antigen), or CD11c (p150,95). PMN
adhesion occurs with the binding of CD11/CD18 to the ligand
intercellular adhesion molecule (ICAM)-1 expressed on the
endothelial surface (Jordan et al., 1999). Hence, PMNs change
shape to motile cells, and transendothelial migration takes
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FIGURE 1 | Schematic mechanism of neutrophil-related oxidative stress in ischemia/reperfusion injury. Reactive oxygen species (ROS) released by neutrophils are
mainly produced by nitric oxide synthase (NOS), NADPH oxidase type 2 (NOX2), and myeloperoxidase (MPO). Although their detrimental role in ischemia reperfusion
injury has been clearly established, a potential effect in promoting tissue healing has been suggested, especially in myocardial injury.
place (Smith, 2000). The latter occurs via paracellular route
through junctions between adjacent endothelial cells and involves
various molecules (PECAM-1, CD99, ICAM-2, endothelial cell-
selective adhesion molecule, and members of the junctional
adhesion molecule family). Once the infarcted zone is infiltrated,
PMNs release ROS alongside cytokines and proteolytic enzymes,
ultimately feeding a vicious circle through a positive feedback
loop (Panth et al., 2016; Montecucco et al., 2017). MPO is
detected within the infarcted myocardium, including the luminal
thrombi on eroded plaques (Ferrante et al., 2010), and MPO-
generated oxidants are likely to have a negligible impact on infarct
size and impact largely on the adverse left ventricle remodeling
and function (Vasilyev et al., 2005). In experimental models,
the mechanism of neutrophil-dependent MRI was shown to
be further dependent on CD18 integrin activation and ICAM-
1 expression by injured cardiac cells (Albelda et al., 1994).
In vivo, ROS are mainly released by adherent PMNs, thus
suggesting the crucial role of the PMN ligand-specific adhesion
to cardiomyocytes in MRI (Frangogiannis, 2015). The generation
of ROS peaks within 2–10 min from coronary artery reperfusion
and acts as a trigger for immune cell chemotaxis – particularly
PMN – through complement activation and upregulation of
cytokines and chemokines via the NF-κB pathway (Hensley et al.,
2000). The role of ROS is of utmost importance in cardiac healing
after AMI as it promotes the clearance of dead cells and cellular
debris. However, exaggerated oxidative stress may result in
detrimental consequences, such as cell apoptosis and degradation
of the extracellular matrix. This occurs when antioxidant systems
(i.e., catalase, glutathione peroxidase, and superoxide dismutase)
and intracellular antioxidants are overcome and the catastrophic
actions of ROS may take place (Frangogiannis, 2015).
Cytochrome P-450 (CYP), xanthine oxidase (XO), NOX,
monoamine oxidase (MAO), and the mitochondrial electron
transport chain (METC) are the most common enzymes involved
in ROS production. CYP is likely the most known source of
ROS in reperfused infarcted heart (Vinten-Johansen, 2004). CYP-
derived ROS increase in an oxygen-dependent way following
increased uncoupling reaction and oxygen supply (Hernandez-
Resendiz et al., 2018). In particular, the release of O−2 and
H2O2 by CYP 2C9 activates the NF-κB pathway which in turn
upregulates the production of proinflammatory cytokines and
the expression of adhesion molecules (Fleming et al., 2001).
Similarly, the overexpression of CYP 2C8 was reported to favor
ROS generation, finally exacerbating coronary vasoconstriction
and increasing infarct size (Edin et al., 2011). XO derives
from xanthine dehydrogenase upon myocardial reperfusion
and reacts with purine substrates and O2 to finally generate
O−2 and H2O2. XO is usually abundant within the vascular
endothelium of normal hearts and is referred to as a primary
source of ROS (Hernandez-Resendiz et al., 2018). This finding
is largely based on the evidence that allopurinol, a known
xanthine oxidoreductase, is effective in limiting the injury
occurring during MRI and reducing the infarcted size (Pisarenko
et al., 1994). Furthermore, XO was described to have a role
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in leukocyte recruitment and neutrophil adhesion in hypoxic
conditions (Matsumura et al., 1998). Concerning NOX, the
subtype NOX2 plays a central role and is typically overexpressed
during MRI. Apart from the role in ROS generation, NOX
can also indirectly provide damages via the activation of PKC-
mediated phosphorylation of the cytosolic p47phox (Patterson
et al., 1999). MAOs can catalyze oxidative deamination of
several monoamines leading to a great production of ROS.
Moreover, MAOs have a role in the production of H2O2 in
the very early reperfusion period (Kunduzova et al., 2002).
Finally, METC complexes are very important sources and targets
of ROS arising during MRI, particularly complexes I and III
(Hernandez-Resendiz et al., 2018). Mitochondrial complex I is
formed by an active A-form and a deactivated D-form, the
latter being the most abundant during MRI and producing O−2
and H2O2 (Gorenkova et al., 2013). Mitochondrial complex
III is another fundamental source of ROS during reperfusion
as demonstrated by the reduced activity in ischemic hearts
compared to healthy ones. Interestingly, ROS burst from the
mitochondria can induce the oxidation of cholesterol and the
production of oxysterols, which induce interleukin-1β release in
the vascular endothelial cells and the following expression of
adhesion molecules for the recruitment of immune cells (Lemaire
et al., 1998; Poli et al., 2013).
Apart from the known detrimental effects of PMNs in
the ischemic area, current evidence suggests that PMNs can
also display reparative functions by recruiting and activating
mononuclear cells (Alard et al., 2015). Recently, neutrophil
depletion by a specific monoclonal antibody has been reported
to not affect infarct size, but rather favor the progressive
deterioration of the post-AMI cardiac function (Horckmans
et al., 2017). Accordingly, the positive influence of PMNs in this
setting may be due to the polarization of macrophages toward a
reparative phenotype mediated, at least partially, by neutrophil
gelatinase-associated lipocalin.
In line with these findings, many antioxidants were studied,
although clinical trials reported some controversial results,
especially with mitochondria-targeted antioxidants (coenzyme
Q10, mitoQ, and MTP-131) (Table 1; Argaud et al., 2005;
Karlsson et al., 2010; Skyschally et al., 2010; Chiari et al., 2014;
Hausenloy et al., 2014; Cung et al., 2015; Dare et al., 2015;
Eleawa et al., 2015; Hernandez-Resendiz et al., 2015; Gibson
et al., 2016; Ottani et al., 2016). Coenzyme Q10 was shown to
decrease the infarcted area, the inflammatory burden, and the
oxidative stress and to normalize left ventricle function following
AMI (Eleawa et al., 2015). MitoQ was studied in IRI after heart
transplantation to reduce ROS production showing to block
graft oxidative damage and blunt the early proinflammatory
response in the recipient. This effect would be dependent on
reducing mitochondrial DNA damage and H2O2 (Dare et al.,
2015). On the contrary, no reduction in myocardial infarct size
was found in the EMBRACE STEMI trial with MTP-131 (also
known as Szeto-Schiller-31 or elamipretide), a cell-permeable
mitochondria-targeting peptide selectively binding to cardiolipin
and optimizing mitochondrial electron transport by reducing
ROS generation (Gibson et al., 2016). The EMBRACE STEMI
was a multicenter, randomized, double-blind phase IIa trial
evaluating the efficacy and safety of MTP-131 vs. placebo infused
at a rate of 0.05 mg/kg/h for 1 h among first-time anterior
STEMI subjects undergoing primary percutaneous coronary
intervention for a proximal or mid left anterior descending artery
occlusion. No reduction of the primary endpoint (infarct size by
creatine kinase–myocardial band and area under the curve over
72 h) was reached as well as no improvement in prespecified
magnetic resonance imaging, angiographic, electrocardiographic,
or clinical outcomes was shown (Gibson et al., 2016). In a similar
manner, cyclosporine A, a potent inhibitor of the mitochondrial
permeability transition pore, showed to significantly reduce
myocardial infarction size in most, but not all, experimental
studies (Argaud et al., 2005; Karlsson et al., 2010; Skyschally et al.,
2010). As well, in some phase II clinical trials, cyclosporine A
was likely to protect the heart following an AMI (Chiari et al.,
2014; Hausenloy et al., 2014). On the contrary, two large clinical
trials reported disappointing results, although a clear explanation
is still lacking. The CYCLE (CYCLosporinE A in Reperfused
Acute Myocardial Infarction) trial of 410 patients ST elevation
AMI did not find any benefit with cyclosporine A administered
prior to primary percutaneous coronary intervention in terms
of ST-segment resolution and enzymatic myocardial infarct
size (Ottani et al., 2016). In the CIRCUS (Does Cyclosporine
Improve Clinical Outcome in ST Elevation Myocardial Infarction
Patients) trial conducted among 970 patients with anterior
ST elevation AMI, cyclosporine A immediately before primary
percutaneous coronary intervention failed to improve clinical
outcomes (all-cause death, heart failure hospitalization, and
adverse left ventricle remodeling) at 1 year (Cung et al., 2015).
For a wider explanation on this topic, readers can be referred to
the review by Hausenloy et al. (2017). Among natural molecules,
curcumin was largely studied as an antioxidant molecule, with
promising direct and indirect effects on ROS scavenging and
myocardial remodeling. An extensive discussion on this topic can
be found elsewhere (Hernandez-Resendiz et al., 2015).
NEUTROPHIL OXIDANTS AND BRAIN
REMODELING
Differently from other peripheral organs, the brain parenchyma
does not elicit stereotypic immune responses. This is largely due
to the unique anatomical composition, as endothelial, epithelial,
and glial barriers tightly regulate the accessibility of immune cells.
The anatomical and functional characteristics of this immune-
privileged organ then imply a different response to IRI despite a
significant gene overlapping (Zhang et al., 2014). The low levels of
antioxidants associated with high polyunsaturated fatty acids in
cellular membranes make the brain more susceptible to oxidative
damage (Adibhatla and Hatcher, 2010). In the early phase of
ischemic IRI, mitochondrial depolarization and activation of XO
determine a first oxidative burst with ROS generation (mainly
O·2 and H2O2). They trigger PMN recruitment and activation,
further precipitating IRI, even more when thrombolytic drugs
are administered. Indeed, we have previously demonstrated
how recombinant tissue-type plasminogen activator induces an
early neutrophil degranulation via PI3K/Akt, which contributes
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TABLE 1 | Efficacy of antioxidant compounds in myocardial ischemia/reperfusion injury.
Author Year Compound Study protocol Correlation with stroke
Eleawa et al., 2015 2015 CoQ10 Male Wistar rats (control, sham, MI without
treatment, CoQ10 then MI)
CoQ10 pre-administration significantly reduced LV infarct
area and normalized LV hemodynamic parameters. CoQ10
also decreased serum BNP and circulating inflammatory
markers (TNF-α, IL-6). These effects were associated with
lowered TBARS scores and concurrent increase in SOD
and GSSH
Dare et al., 2015 2014 MitoQ Heart transplant model in C57BL/6 mice
[control, MitoQ; all exposed to short (30 min) or
prolonged (4 h) cold preservation]
MitoQ to the donor heart protected against this I/R injury by
blocking graft oxidative damage and dampening the early
pro-inflammatory response in the recipient.
Gibson et al., 2016 2016 MTP-131 118 patients with anterior STEMI undergoing
first-time PCI plus stenting within <4 h (i.v.
MTP-131 at 0.05 mg/kg/h or appearing
placebo)
MTP-131 failed in significantly reducing infarct size.
MTP-131 was not associated with any improvement in
magnetic resonance imaging, angiographic,
electrocardiographic, or clinical outcomes
Argaud et al., 2005 2005 NIM811
(cyclosporin A
derivative)
NZW rabbit [sham or I/R (10/5 min)
preconditioned or not].
NIM811 increases the Ca2+ overload required to induce
MPTP opening. NIM811 also reduced both necrotic and
apoptotic cardiomyocyte death.
Skyschally et al.,
2010
2010 Cyclosporin A Göttinger minipigs [sham or I/R (90/120 min) or
post-conditioning]
Both cyclosporine A at reperfusion and ischemic
post-conditioning failed to reduced infarct size more than
controls
Karlsson et al., 2010 2010 Cyclosporin A Pigs [CsA (10 mg/kg) or placebo] Cyclosporine A did not reduce IS/AAR compared with
placebo. Rather, apoptosis-inducing factor protein
expression was higher in the cyclosporine A group, thus
suggesting a potential deleterious effect.
Hausenloy et al.,
2014
2014 Cyclosporin A 78 patients undergoing elective CABG surgery
[CsA (2.5 mg/kg) or placebo]
There was no significant difference in mean peak cTnT.
However, in higher-risk patients peri-operative myocardial
injury (post-operative cTnT) was reduced in the
cyclosporine A group.
Chiari et al., 2014 2017 Cyclosporin A 61 patients undergoing elective aortic valve
surgery [CsA (2.5 mg/kg) or placebo]
A significant 35% reduction of area under the curve for cTnI
was observed in the cyclosporine group
Ottani et al., 2016 2016 Cyclosporin A 410 patients with anterior STEMI undergoing
PCI [CsA (2.5 mg/kg) or placebo]
The two groups did not differ in TnI rise or LVEF both at day
4 and at 6 months. IS did not influence CsA efficacy.
Cung et al., 2015 2015 Cyclosporin A 970 patients with large STEMI within 6 h from
onset [CsA (2.5 mg/kg) or placebo]
Cyclosporine A failed to reduce the rate of composite
outcome as well as that of separate clinical components.
No significant difference in the safety profile was observed
between the two treatment groups.
Hernandez-Resendiz
et al., 2015
2015 Curcumin Male Wistar rats [curcumin (120 mg/kg/day)
after 5/6 nephrectomy]
Curcumin restored sBP, myocardial wall thickening, LVEDV,
and LVEF in nephrectomized rats. Also, it diminished
MMP-2 levels and overall gelatinase activity, oxidative
stress, and MPTP opening.
AAR, area at risk; BP, blood pressure; BNP, brain natriuretic peptide; CABG, coronary artery bypass graft; CsA, cyclosporin A; cTNI, cardiac troponin I; cTNT, cardiac
troponin T; I/R, ischemia/reperfusion; IL, interleukin; IS, infarct size; LV, left ventricle; LVEDV, left ventricle end diastolic volume; LVEF, left ventricle ejection fraction;
MMP, metalloproteinase; MPTP, mitochondrial permeability transition pore; PCI, percutaneous coronary intervention; SOD, superoxide dismutase; STEMI, ST elevation
myocardial infarction; TBARS, thiobarbituric acid reactive substances; TNF, tumor necrosis factor.
to the increased risk of hemorrhagic transformation (Carbone
et al., 2015b,c). PMNs then represent the leading source of ROS
in the subacute phase of stroke. Experimental models largely
emphasized the detrimental effect of NOX2 activation in the
ischemic brain, being brain swelling and infarct size significantly
reduced in NOX2−/− mice. In this context, especially ·OH
has been described as typical phagocyte ROS and amplifier of
ischemic injury on neuronal cells. ·OH is generated via the
Fenton reaction and has great affinity for unsaturated fatty acids,
ultimately leading to peroxyl radical (ROOS) generation. In turn,
ROOS trigger a cycle of lipid peroxidation that destroys cellular
membranes. Products of lipid peroxidation further sustain
oxidative stress by generating aldehydes, dienals, or alkanes (e.g.,
malondialdehyde and 4-hydroxynonenal). The consequent redox
unbalance leads to neuronal apoptosis and blood–brain barrier
(BBB) breakdown.
More recently, NO has been suggested as an additional
mediator of IRI. At low oxygen concentrations, NO accumulates
and reacts with O·2 to generate peroxynitrite. Nitrosative
stress may lead to BBB breakdown, inflammation, and caspase
activation, which ultimately lead to cell apoptosis through
interacting with different cellular signaling pathways including
matrix metalloproteinase, high-mobility group box 1, toll-like
receptors 2 and 4, poly(ADP-ribose) polymerase, Src, Rho-
associated protein kinase (ROCK), and glycogen synthase
kinase (GSK)-3β (Radi et al., 2015). Oxidative stress may also
influence epigenetic mechanisms (i.e., DNA methylation, histone
modification, microRNAs) (Zhao et al., 2016; Narne et al., 2017),
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TABLE 2 | Efficacy of antioxidant compounds in stroke.
Author Year Number of patient Study design
(follow-up)
Correlation with stroke
Edaravone
Kono et al., 2013 2013 129 stroke patients Retrospective analysis
(7 and 90 days)
Edaravone was associated with higher recanalization rate (p < 0.01)
and better mRS (p < 0.01).
Wada et al., 2014 2014 6336 stroke patients Retrospective analysis
(discharge)
Edaravone improved mRS score at discharge [OR 0.74 (95% CI
0.57–0.96); p = 0.024], without modifying length of hospital stay,
hemorrhagic transformation, or in-hospital mortality.
Yamaguchi et al., 2017 2017 8274 stroke patients
from PROTECT4.5 and
SITS-ISTR studies
Retrospective analysis
(90 days)
The combination of edaravone with r-tPA is associated with mRS
improvement in patients with NIHSS score ≥ 16 (p < 0.05).
Lee and Xiang, 2018 2018 38 stroke patients Prospective
randomized trial (7 and
14 days)
Edaravone group was characterized by improved NIHSS score both at
days 7 and 14 (p < 0.05 for both). Edaravone group also showed
higher recanalization and lower rate of hemorrhagic transformation and
bleeding complications (p < 0.05 for all).
Uric acid
Logallo et al., 2011 2011 1136 stroke patients Observational (7 and
90 days)
After tertile categorization, SUA correlated with early clinical
improvement (r = 0.012; p = 0.02) and long-term favorable outcome
[OR 1.004 (95% CI 1.001–1.009); p = 0.04].
Liu et al., 2015 2015 216 stroke patients Prospective
observational (90 days)
In multivariate models, increased SUA levels were associated with
excellent outcomes [OR 1.005 (95% CI 1.002–1.009); p = 0.033]
Llull et al., 2015 2015 411 stroke patients Prospective
interventional (90 days)
UA therapy doubled the effect of placebo in improving stroke outcome
in women [OR 2.088 (95% CI 1.050–4.150); p = 0.036], but not in men.
Chamorro et al., 2017 2017 421 stroke patients
from URICO-ICTUS trial
Prospective
interventional (90 days)
The addition of UA to thrombolysis improved functional outcome [OR
6.12 (95% CI 1.08–34·56); p < 0·05] in absence on any safety
concerns.
CI, confidence interval; mRS, modified Rankin Scale; NIHSS, National Institute of Health Stroke Scale; OR, odds ratio; r-tPA, recombinant tissue-type plasminogen
activator; RR, relative risk; SUA, serum uric acid.
well known to be implicated in neuroprotection (Felling and
Song, 2015; Simon, 2016; Chandran et al., 2017). Therefore, it has
been suggested that ROS may contribute themselves to neuronal
recovery after ischemic stroke. In line with this hypothesis,
ROS-induced activation of HIF-1α/β-catenin pathway has been
associated with neuronal recovery in rats (Hu et al., 2014),
whereas a biphasic role of ROS has been recently suggested also
in human beings (Yang et al., 2018). Furthermore, oxidative
stress (mainly H2O2 and NOX signaling) regulates neural stem
and progenitor cell proliferation, self-renewal, and neurogenesis
(Le Belle et al., 2011). As compared with ·OH, ROS are generated
constantly as part of a normal aerobic life and are active players
of several metabolic pathways ranging from cell adhesion to
lipid metabolism (Roy et al., 2017). Nevertheless, the extent to
which the redox status potentially contributes to brain recovery
has not been established yet. Rather, a large body of evidence
indicates the suppression of oxidative stress as a promising
strategy to reduce brain injury. Improving reperfusion is
certainly the best approach to reduce ROS generation (Carbone
et al., 2018a; Chamorro, 2018; Taskiran-Sag et al., 2018).
Furthermore, it is likely that antioxidant compounds tested
in previous neuroprotection trials might be more effective if
reperfusion therapies are co-administered (Chamorro, 2018).
Among different antioxidant compounds, edaravone has
already been used for years in the Far East countries. As a free
radical scavenger with inhibitory effects on lipid peroxidation
(Yamamoto, 2017), edaravone promotes neuroprotection
when combined with thrombolysis (Logallo et al., 2011;
Kono et al., 2013; Wada et al., 2014; Liu et al., 2015; Llull
et al., 2015; Chamorro et al., 2017; Yamaguchi et al., 2017; Lee
and Xiang, 2018; Table 2). Surprisingly, free radical scavenging
properties have also been described for uric acid (UA). Serum
levels of UA are classically associated with increased CV risk, but
this association may rather be a compensatory mechanism (Li
et al., 2015). Furthermore, when administered with recombinant
tissue-type plasminogen activator, UA significantly improves
the efficacy of thrombolysis (Logallo et al., 2011; Liu et al.,
2015; Llull et al., 2015; Chamorro et al., 2017; Table 2).
Other classes of compounds are currently under evaluation in
preclinical studies and include a synthetic analog of vitamin
E and specific inhibitors of NOX and NOS (Sun et al., 2018).
Finally, some advances in nanomedicine are expected to
improve drug delivery (Zhang et al., 2017; Shen et al., 2018)
or even provide new nanoparticles with antioxidant potential
(Hosoo et al., 2017).
CONCLUSION
Free radicals have strong oxidative properties in ischemic
tissues. When reperfusion occurs, the massive generation of
ROS and reactive nitrogen species leads to cell death via
DNA damage, protein dysfunction, and lipid peroxidation.
However, signaling pathways activated by oxidative stress are
also likely to be involved in the healing processes. Appropriate
consideration of the role of PMN-related oxidative stress in IRI
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might potentially improve current therapeutic strategies.
However, several critical points should be taken into account.
PMN-generated ROS may have both detrimental and beneficial
roles in different models of IRI. This dual role might depend on
the cell and tissue types and the timing of response (Montecucco
et al., 2017). ROS activity is not limited to nearby cells/tissues.
Rather there is variability in the diffusion range due to the
different life span and reactivity. Finally, the side effects induced
by immune suppression should be considered (Horckmans et al.,
2017). Addressing these issues may explain how the results
of clinical trials have so far failed to reproduce the success of
preclinical studies.
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